HOMAGE is a 6-year European research network (Collaborative Project) supported by the European Commission under the Health Cooperation Work Programme of the 7th Framework Programme, under the Grant Agreement n°305507
 |
 |
Collaborative Partners
The Trustees of Boston University: National Heart, Lung, and Blood Institute’s Framingham Heart Study (UB)
The Framingham Heart Study is a longitudinal community-based cohort funded by the National Heart, Lung, and Blood Institute, and operated in conjunction with Boston University via NIH contract and grant funding mechanisms. The study began in 1948 by recruiting an original cohort of 5,209 men and women age 28 to 62 years from the town of Framingham, MA. Since then, the contributions of 3 generations of participants and numerous investigators have made the Framingham Heart Study a prototype for other epidemiological studies around the world and established the utility of the risk factor concept for gaining invaluable insights into the development and prevention of chronic diseases.
Dr. Daniel Levy, Dr. Jennifer Ho will serve in a scientific advisory role on the data analysis phase in the identification of biomarker fingerprints of heart failure. In addition, future collaboration with regard to reciprocal exchange of specific –omics based heart failure biomarkers will be considered, where the Framingham Heart Study (UB) may serve as an independent replication cohort for biomarkers emanating from HOMAGE and conversely, to take UB discovered biomarkers to HOMAGE for replication. Any such effort will need to be approved separately via established UB ancillary study procedures.
Daniel Levy, M.D. is a Scientific Director with the National Heart, Lung, and Blood Institute where he serves as Director of the Center for Population Studies and Director of the Framingham Heart Study.
Dr. Levy’s main areas of research interest include the epidemiology and genetics of hypertension, heart disease and heart failure. He is spearheading a new research program known as the SABRe CVD Initiative (Systems Approach to Biomarker Research in Cardiovascular Disease) that seeks to identify new biomarkers and pathways involved in cardiovascular disease through gene expression profiling and discovery proteomics and metabolomics. These resources will be united with Framingham’s unparalleled genetic and phenotypic databases and will be made freely accessible to the public.
In addition to his research and administrative responsibilities, Dr. Levy has become actively involved as a policy maker. He served with the National High Blood Pressure Education Program and the National Cholesterol Education Program in the formulation of our national hypertension and cholesterol guidelines. He is currently working with National Heart, Lung, and Blood Institute on the development of new cholesterol guidelines and risk assessment methods for those guidelines.
Dr. Levy received a Bachelor of Arts degree from the University of Pennsylvania and an M.D. degree from Boston University School of Medicine. He completed a residency in internal medicine at University Hospital, Boston and a research fellowship in cardiology at Brigham and Women’s Hospital, and Harvard School of Public Health. He joined the National Heart, Lung, and Blood Institute and the Framingham Heart Study in 1984 and became the Study’s fourth director in 1994. In 2005, he returned to the classroom as a fellow in Medical Ethics at Harvard Medical School. Dr. Levy has a faculty appointment at Boston University School of Medicine, where he is Professor of Medicine and he holds an adjunct appointment at Harvard Medical School. Dr. Levy has been the recipient of many awards and twice received the National Institutes of Health Director’s Award for his research accomplishments. In November 2009 he was the recipient of the American Heart Association’s highest recognition for research achievements in epidemiology, the Population Research Prize. Dr. Levy has mentored scores of research fellows and has published over 400 articles in leading medical journals. He authored a book about the revolution in understanding of heart disease titled “A Change of Heart” (published by Alfred A. Knopf), and is Editor-in-Chief of the journal Current Cardiovascular Risk Reports. Dr. Levy is a fellow of the American College of Cardiology and of the American Heart Association.
Imperial College of London
Imperial College, London (UK) will contribute to the provision of data and biological samples from the ASCOT Trial of well characterized patients and subjects enrolled in this large-scale multicenter clinical trial in patients with high CV risk. It will also participate to the design of analysis plan and to the drafting scientific reports derived from the analysis of these samples. Pr Sever will serve in a scientific advisory role on the data analysis phase in the identification of biomarker fingerprints of heart failure.
Peter Sever is Professor of Clinical Pharmacology and Therapeutics at Imperial College London and Honorary Consultant Physician at the Imperial College Healthcare NHS Trust. He is co-Director of the International Centre for Circulatory Health and Head of the Disease Prevention Section of the National Heart and Lung Institute, Imperial College London. In 2009, was appointed as a Senior Investigator of the National Institute for Health Research.
Professor Sever’s research interests include the pathophysiology of vascular disease, the evaluation of antihypertensive drug therapy and the impact of multiple risk factor intervention for the prevention of cardiovascular disease.
After graduating from the University of Cambridge, Professor Sever completed his training at St Mary’s Hospital Medical School in London. He became an Honorary Consultant Physician and Senior Lecturer in Medicine at St Mary’s Hospital in 1976. In 1980, he was appointed Professor of Clinical Pharmacology and Therapeutics at St Mary’s Hospital Medical School, which was subsequently incorporated into the Imperial College School of Medicine. Professor Sever is Joint Editor-in-Chief of the Journal of the Renin-Angiotensin-Aldosterone System. Professor Sever is a past President of the British Hypertension Society and the European Council for Blood Pressure and Cardiovascular Research and past Chairman of the Fellowships Committee of the British Heart Foundation. He is also a Fellow of the European Society of Cardiology. In 2010, he was presented with the AstaZeneca Award from the International Society for Hypertension for his contribution to the clinical pharmacology and therapy of arterial hypertension.
Steno Diabetes Center (Novo Nordisk)
Steno Diabetes Center (Novo Nordisk) will contribute to the provision of data and biological samples from the ongoing PRIORITY Trial of well characterized patients enrolled in this large-scale multicenter clinical trial in patients with diabetes. This at risk patients are at risk of developing new onset heart failure. Pr Rossig will also participate to the design of analysis plan and to the drafting scientific reports derived from the analysis of these samples and serve in a scientific advisory role on the data analysis phase in the identification of biomarker fingerprints of heart failure. The main objective of the PRIORITY trial is very complementary and similar to the HOMAGE trial. It aims to develop an intervention strategy to prevent development of diabetic nephropathy based on the application of the urinary proteomics test to identify high risk patients and subsequent treatment by the use of aldosterone blockade as a means to reduce progression to microalbuminuria.
|
Peter Rossing, MD, DMSc Director of Research of the Steno Diabetes Center
Steno Diabetes Center Niels Steensens Vej 2 2820 Gentofte Denmark
|
Peter Rossing has since 2007 been a chief physician and manager of the Steno Diabetes Center research team dedicated to the research of micro-and macrovascular complications of diabetes. Since 2010 Head of Research at SDC and from 2012 adjunct professor at University of Aarhus and University of Copenhagen in diabetic angiopathy. The particular focus has been on diabetic nephropathy and macroangiopathy. The research has included prevention and treatment of these complications. Furthermore there has been focus on risk prediction and biomarker discovery. Coordinator of the EU FP7 sponsored project PRIORITY for early prevention of diabetic nephropathy. PR has co-authored >200 papers, 29 as a first author. 139 of the papers are original and peer reviewed contributions, 20 are reviews or invited chapters, and his h-index is 43. PR has received several national and international awards including The Minkowski prize from the EASD in 2005 and the Novarits Young Investigator Diabetes Prize 2009.
Specialist in Internal medicine and endocrinology October 2004
DMSc at Univ of Copenhagen 1998 “Promotion, prediction and prevention of progression in diabetic nephropathy”
Professional Positions 2008- Danish Endocrine Society – president 2012. 2009- Danish Hypertension Society – member of the board 2006-2010 European Diabetic Nephropathy Study group – member of the board 2011- Co-Chair of Danish National Indicator Project for Diabetes Positions 11.02.91 - 30.09.94 Hvidöre Hospital/Steno Diabetes Center 01.10.94 - 29.02.96 Steno Education Center, Course coordinator 01.03.96-31.08.96 Sygehuset Øresund, Helsingør, Surgery (registrar) 01.09.96-28.2.97 Hillerød sygehus Med dept B (registrar) 01.03.97-31.08.97 GP Lægehuset i Frederikssund 01.09.97-30.09.97 Registrar: Med dept Roskilde Amtssygehus 01.10.97-30.09.98 Registrar: Med dept F KAS Herlev 01.10.98-31.08.99 Registrar: Med dept F KAS Gentofte 01.09.99-31.08.00 Registrar: Med dept CF KAS Glostrup 01.09.00-28.02.01 Registrar: Dept of nephrology KAS Herlev 01.03.01-31.08.01 Registrar: Dept of Oncology KAS Herlev 01.09.01-31.03.02 Senior, Dept of Medicine F KAS Gentofte 01.04.02-31.12.04 Senior, Dept of Endocrinology, University of Copenhagen, Herlev Hospital 01.01.05-31.12.2006 Senior registrar Steno Diabetes Center (SDC), 01.01.2007- Chief physician and manager of complications research SDC 01.01.2010- Head of Research SDC, Adjunct professor in diabetic angiopathy, HEALTH University of Aarhus, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen
